|drug2698||Questionnaire-based observational study Wiki||0.71|
|D011024||Pneumonia, Viral NIH||0.08|
|D018352||Coronavirus Infections NIH||0.05|
There are 2 clinical trials
The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib (RUX) and fostamatinib (FOS) individually, compared to standard of care in the treatment of COVID-19 pneumonia. The primary outcome is the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia. Patients are treated for 14 days and will receive follow-up assessment at 7, 14 and 28 days after the first study dose. Patients with mild or moderate COVID-19 pneumonia will be recruited. Initially, n=171 (57 per arm) patients will be recruited in Stage 1. Following interim analysis to assess the efficacy and safety of the treatments, approximately n=285 (95 per arm) will be recruited during Stage 2.
Description: Scale range from 0 (uninfected) to 9 (dead)Measure: Absolute change in pneumonia severity on the modified WHO COVID-19 Ordinal Scale Time: Day 14, 28
The study is a double-blind, randomized, placebo-controlled, adaptive design, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.
Description: Progression to severe/critical disease within 29 days of first dose of study treatmentMeasure: Progression to severe/critical disease within 29 days of first dose of study treatment Time: 29 days
Description: Proportion of subjects transferred into the intensive care unit (ICU) or who died prior to Day 29Measure: Proportion of subjects transferred into the intensive care unit (ICU) or who died prior to Day 29 Time: 29 days
Description: Total number of calendar days hospitalized through Day 29Measure: Total number of calendar days hospitalized through Day 29 Time: 29 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports